MX2021002647A - Metodos de tratamiento de la psoriasis. - Google Patents

Metodos de tratamiento de la psoriasis.

Info

Publication number
MX2021002647A
MX2021002647A MX2021002647A MX2021002647A MX2021002647A MX 2021002647 A MX2021002647 A MX 2021002647A MX 2021002647 A MX2021002647 A MX 2021002647A MX 2021002647 A MX2021002647 A MX 2021002647A MX 2021002647 A MX2021002647 A MX 2021002647A
Authority
MX
Mexico
Prior art keywords
methods
treating psoriasis
treatment
psoriasis
subunit
Prior art date
Application number
MX2021002647A
Other languages
English (en)
Inventor
Stuart William Friedrich
Jay Lawrence Tuttle
Paul Alan Klekotka
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021002647A publication Critical patent/MX2021002647A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere en general al tratamiento de la psoriasis con un anticuerpo que se une a la subunidad p19 de la IL-23 humana, en particular regímenes de dosificación para el tratamiento de la enfermedad.
MX2021002647A 2018-09-11 2019-09-05 Metodos de tratamiento de la psoriasis. MX2021002647A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862729435P 2018-09-11 2018-09-11
PCT/US2019/049648 WO2020055651A1 (en) 2018-09-11 2019-09-05 Methods of treating psoriasis

Publications (1)

Publication Number Publication Date
MX2021002647A true MX2021002647A (es) 2021-09-14

Family

ID=67998728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002647A MX2021002647A (es) 2018-09-11 2019-09-05 Metodos de tratamiento de la psoriasis.

Country Status (15)

Country Link
US (1) US20220064280A1 (es)
EP (1) EP3849603A1 (es)
JP (2) JP7203988B2 (es)
KR (2) KR20210042138A (es)
CN (1) CN112638420A (es)
AU (1) AU2019337530B2 (es)
BR (1) BR112021003209A2 (es)
CA (1) CA3112579A1 (es)
EA (1) EA202190504A1 (es)
IL (1) IL281284A (es)
MA (1) MA53602A (es)
MX (1) MX2021002647A (es)
SG (1) SG11202102240YA (es)
TW (2) TWI808397B (es)
WO (1) WO2020055651A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123477A1 (es) * 2020-09-10 2022-12-07 Lilly Co Eli Formulaciones de anticuerpos terapéuticos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3074828A (en) * 1960-02-01 1963-01-22 Mcdonnell Aircraft Corp Exothermic heated metal for heat treating and forming
CN103813804A (zh) * 2010-10-06 2014-05-21 Abbvie公司 用于治疗银屑病的方法
CA2813900C (en) 2010-10-08 2017-01-10 Novartis Ag Methods of treating psoriasis using il-17 antagonists
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
WO2017221174A1 (en) * 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies

Also Published As

Publication number Publication date
KR20210042138A (ko) 2021-04-16
TWI725532B (zh) 2021-04-21
JP2022500498A (ja) 2022-01-04
US20220064280A1 (en) 2022-03-03
TW202134274A (zh) 2021-09-16
EA202190504A1 (ru) 2021-06-10
IL281284A (en) 2021-04-29
WO2020055651A1 (en) 2020-03-19
JP7203988B2 (ja) 2023-01-13
CA3112579A1 (en) 2020-03-19
TWI808397B (zh) 2023-07-11
EP3849603A1 (en) 2021-07-21
BR112021003209A2 (pt) 2021-05-11
AU2019337530B2 (en) 2023-08-10
TW202023615A (zh) 2020-07-01
CN112638420A (zh) 2021-04-09
SG11202102240YA (en) 2021-04-29
MA53602A (fr) 2021-12-15
JP2023036875A (ja) 2023-03-14
AU2019337530A1 (en) 2021-03-18
KR20230141933A (ko) 2023-10-10

Similar Documents

Publication Publication Date Title
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2017003565A (es) Anticuerpos anti-edad para el tratamiento de inflamacion y trastornos autoinmunes.
PH12017500493A1 (en) Combination therapy
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2022015248A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MX2019003235A (es) Metodos para tratar dermatitis atopica severa administrando un inhibidor de receptor de isoleucina-4.
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
CO2019003865A2 (es) Proteína terapéutica
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2017014396A (es) Tratamiento de mieloma multiple.
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2021002647A (es) Metodos de tratamiento de la psoriasis.